One Pill Instead of Two Medications: New Approach Improves Diabetes Control

The study involved 536 adults whose glycated hemoglobin (HbA1c) levels — a measure of average blood sugar over the previous two to three months — remained elevated despite treatment. Over a 16-week period, some participants received a combination of three medications: dapagliflozin, glimepiride, and metformin. Others took glimepiride and metformin in separate pills.

Glycated hemoglobin levels decreased more significantly in both groups receiving the three-drug combination. Depending on the dosage, the reduction ranged from 2.17 to 2.25 percentage points, compared with 1.64 to 1.72 percentage points in the two-drug treatment groups.

The target glycated hemoglobin level of below 7% was achieved by approximately 71% of participants in the group receiving the lower dose of metformin and 78% in the group receiving the higher dose. Among those treated with two medications, the corresponding figures were approximately 47% and 53%.

The incidence of adverse events was comparable across all four groups. During the main study period, 26 adverse events were reported, including fever, vomiting, and headache. All were mild or moderate. The researchers identified no serious adverse events or episodes of hypoglycemia, a potentially dangerous drop in blood sugar levels.

The authors note that combining three medications in a single pill could simplify treatment and reduce the number of tablets patients need to take daily. However, the study did not directly assess whether this approach improves treatment adherence.

The study has several limitations: it was relatively short, conducted exclusively in India, and did not include patients with certain serious diabetes-related complications. The researchers emphasize the need for longer-term follow-up to assess the treatment's long-term safety and its impact on the risk of complications.